2. Cell Cycle/DNA Damage
  3. CDK
  4. Anticancer agent 300

Anticancer agent 300 (compound P14) is a CCND1, CDK4, CDK6, and CCNE1 modulator, with anti-proliferative, cell-cycle modulatory, senescence-inducing, and apoptosis-inducing activity. Anticancer agent 300 can be used for the research of ER+/HER2− breast cancer and BRAF-mutant melanoma.

For research use only. We do not sell to patients.

Anticancer agent 300

Anticancer agent 300 Chemical Structure

CAS No. : 1310059-06-3

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Anticancer agent 300 Related Antibodies

Top Publications Citing Use of Products

View All CDK Isoform Specific Products:

View All Isoforms
CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85 CDK10 CDK15 CDK17 CDK18 CDK20 PITSLRE

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Anticancer agent 300 (compound P14) is a CCND1, CDK4, CDK6, and CCNE1 modulator, with anti-proliferative, cell-cycle modulatory, senescence-inducing, and apoptosis-inducing activity. Anticancer agent 300 can be used for the research of ER+/HER2− breast cancer and BRAF-mutant melanoma[1].

In Vitro

Anticancer agent 300 (P14) (5-50 μM; 7 days) significantly reduces colony-forming capacity in MCF7 and A375 cells and induces cytotoxicity in non-tumoral TC28a2 cells at high concentrations[1].
Anticancer agent 300 (P14) (5-50 μM; 7 days) has an IC50 of 2.018 μM in MCF7 cells and 1.887 μM in A375 cells[1].
Anticancer agent 300 (P14) (5 μM; 12 days) significantly reduces spheroid area in MCF7 and A375 3D cultures[1].
Anticancer agent 300 (P14) (5 μM; 7 days) reduces the proportion of G2/M phase cells in MCF7 and A375 cells[1].
Anticancer agent 300 (P14) (5 μM; 7 days) modulates the expression of cell-cycle-related genes in a cell-type-specific manner, upregulating G1/S transition genes in MCF7 cells and downregulating them in A375 cells[1].
Anticancer agent 300 (P14) (5 μM; 7 days) increases the expression of senescence-associated genes in MCF7 and A375 cells[1].
Anticancer agent 300 (P14) (5 μM; 7 days) upregulates SASP factors in MCF7 cells and reduces their synthesis in A375 cells[1].
Anticancer agent 300 (P14) (5 μM; 7 days) increases cell death and early apoptosis in MCF7 and A375 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anticancer agent 300 Related Antibodies

Cell Proliferation Assay[1]

Cell Line: MCF7, A375, TC28a2
Concentration: 5, 20, 35, 50 μM
Incubation Time: 7 days
Result: Significantly reduced the colony-forming capacity of MCF7 and A375 cells in a dose-dependent manner. Demonstrated potent anti-proliferative effects even at 5 μM in both cell lines. Induced cytotoxicity in non-tumoral TC28a2 cells at high concentrations (up to 20 μM).

Cell Proliferation Assay[1]

Cell Line: MCF7, A375
Concentration: 5, 20, 35, 50 μM
Incubation Time: 7 days
Result: Achieved an IC50 of 2.018 μM in MCF7 cells and 1.887 μM in A375 cells.

Cell Proliferation Assay[1]

Cell Line: MCF7, A375
Concentration: 5 μM
Incubation Time: 12 days
Result: Significantly reduced spheroid area in MCF7 cells after 8 and 12 days of treatment, and in A375 cells with a less marked but still statistically significant reduction.

Cell Cycle Analysis[1]

Cell Line: MCF7, A375
Concentration: 5 μM
Incubation Time: 7 days
Result: Reduced the proportion of cells in the G2 phase in both cell lines: decreased MCF7 cells' G2/M phase proportion from 26.25% (control) to 13.10%, and A375 cells' G2/M phase proportion from 5.44% (control) to 0.52%.

Real Time qPCR[1]

Cell Line: MCF7, A375
Concentration: 5 μM
Incubation Time: 7 days
Result: Significantly upregulated genes associated with G1/S transition and S-phase entry in MCF7 cells. Significantly downregulated key regulators of the G1/S transition and S-phase entry, including CCND1, CDK4, CDK6, and CCNE1, in A375 cells.\nNotably increased the expression of senescence-associated factors, including p21, p53, and p53-responsive genes (IGFBP3 and GDF15), in both cell lines.\nSignificantly upregulated classical SASP components, including IL-6 and IL-8, in MCF7 cells. Showed a trend toward reduced synthesis of SASP factors in A375 cells.

Apoptosis Analysis[1]

Cell Line: MCF7, A375
Concentration: 5 μM
Incubation Time: 7 days
Result: Showed a tendency to increase cell death and the proportion of cells undergoing early apoptosis in both cell lines.
Molecular Weight

429.56

Formula

C24H19N3OS2
CAS No.
SMILES

C12=C(SC(C3=CC(C4=CC5=C(S4)C=CC=C5)=NC(N6CCOCC6)=N3)=C2)C=CC=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Anticancer agent 300 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Anticancer agent 3001310059-06-3Anticancer agent300Anticancer agent-300CDKCyclin dependent kinaseCDK4A375 cellsBRAF-mutant melanomaCCND1breast cancer cellsMCF7 cellsER+/HER2? breast cancerCCNE1melanoma cellsCDK6Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Anticancer agent 300
Cat. No.:
HY-181131
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.